TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT02525692

Oral ONC201 in Adult Recurrent Glioblastoma

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.
“The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201 in an earlier setting. This decision was unrelated to any safety concerns with dordaviprone (ONC201).”

The sponsor’s own words in the registry.

Life of this trial

20152016201720182019202020212022202320242025Registered2015-08-14Started2016-01Stopped2023-04-17Results posted2024-12-24

Vital statistics

Status
Terminated
Phase
Phase 2
Sponsor
Jazz Pharmaceuticals
Sponsor type
Industry
Conditions
Glioblastoma; Diffuse Midline Glioma; H3 K27M Glioma; Thalamic Glioma; Infratentorial Glioma; Basal Ganglia Glioma
Interventions
Dordaviprone (ONC201)
Participants
84
Sites
5
Countries
United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.